A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Ulcerative Colitis
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Upadacitinib (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms U-Accomplish
- Sponsors AbbVie; AbbVie Germany
- 12 Apr 2019 Planned End Date changed from 23 Feb 2022 to 23 Feb 2021.
- 12 Apr 2019 Planned primary completion date changed from 23 Feb 2022 to 23 Feb 2021.
- 28 Jan 2019 Planned End Date changed from 3 Jul 2024 to 23 Feb 2022.